The revenue for CFT-7455 is expected to reach an annual total of $131 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

CFT-7455 Overview

Cemsidomide (CFT-7455) is under development for the treatment of relapsed or refractory multiple myeloma (MM), mantle cell lymphoma (MCL), follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphomas (PTCL) including Anaplastic Large Cell Lymphoma. The drug candidate is a molecular glue degrader. It is administered by the oral route and acts by targeting IKZF1 and IKZF3. It is being developed based on the TORPEDO platform (Target ORiented ProtEin Degrader Optimizer).

C4 Therapeutics Overview

C4 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for cancer treatments. The company utilizes its platform, TORPEDO (target-oriented protein degrader optimizer) which designs and optimizes small-molecule medicines to address difficult-to-treat diseases. Its pipeline includes various drug programs such as CFT7455 to treat multiple myeloma and non-Hodgkin’s lymphoma; CFT1946 for the treatment of V600 mutant cancer; and CFT8919 to treat non-small cell lung cancer. C4 Therapeutics is also developing other undisclosed programs for cancer treatment. The company works in collaboration with Roche, Biogen, Betta Pharmaceuticals, Merck, and Merck KGaA. C4 Therapeutics is headquartered in Watertown, Massachusetts, the US.
The company reported revenues of (US Dollars) US$20.8 million for the fiscal year ended December 2023 (FY2023), a decrease of 33.3% over FY2022. The operating loss of the company was US$139.7 million in FY2023, compared to an operating loss of US$129.5 million in FY2022. The net loss of the company was US$132.5 million in FY2023, compared to a net loss of US$128.2 million in FY2022.

For a complete picture of CFT-7455’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.